Pyxis oncology stock prediction
Pyxis Oncology, Inc. (PYXS) Share Price Forecast v/s Share Price Today Below is a chart showing the percentage difference between Pyxis Oncology, Inc.'s share price and its median forecast price. As on 27.11.23, the difference is -75.29%Their RAIN share price targets range from $11.00 to $24.00. On average, they anticipate the company's stock price to reach $17.00 in the next year. This suggests a possible upside of 1,431.5% from the stock's current price. View analysts price targets for RAIN or view top-rated stocks among Wall Street analysts.
Did you know?
View the latest Pyxis Oncology Inc. (PYXS) stock price, news, historical charts, analyst ratings and financial information from WSJ. As of August 15, 2022, the outstanding number of shares of Common Stock of Pyxis Oncology was 32,834,561. About Pyxis Oncology, Inc. Pyxis Oncology, Inc. is an oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. By leveraging our fully ...May 12, 2023 · Pyxis Oncology Inc (PYXS) stock is up 9.87% while the S&P 500 is lower by -0.69% as of 2:04 PM on Friday, May 12. PYXS has risen $0.30 from the previous closing price of $3.04 on volume of 1,647,588 shares. Over the past year the S&P 500 has risen 4.24% while PYXS has risen 57.55%. PYXS lost -$3.65 per share in the over the last 12 months.
The stock options have a ten-year term and an exercise price of $4.01, the closing price of Pyxis Oncology’s common stock as reported by Nasdaq on March 31, 2023.Nastassia Samal. Pfizer ( PFE) backed Pyxis Oncology ( NASDAQ: PYXS) is acquiring Apexigen ( NASDAQ: APGN) in an all stock deal, for a total enterprise value of ~$16M. Under the agreement, Pyxis ...May 12, 2023 · Pyxis Oncology Inc (PYXS) stock is up 9.87% while the S&P 500 is lower by -0.69% as of 2:04 PM on Friday, May 12. PYXS has risen $0.30 from the previous closing price of $3.04 on volume of 1,647,588 shares. Over the past year the S&P 500 has risen 4.24% while PYXS has risen 57.55%. PYXS lost -$3.65 per share in the over the last 12 months. A high-level overview of Pyxis Oncology, Inc. (PYXS) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Asset Growth. -27.76%. Trailing 12-Months. The Pyxis Oncology stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and ...
Pyxis Oncology (PYXS) Stock Price, News & Analysis $1.44 +0.01 (+0.70%) (As of 11/20/2023 ET) Compare Share Today's Range $1.42 $1.48 50-Day …Analyst Price Forecast Suggests 349.06% Upside As of November 27, 2023, the average one-year price target for Pyxis Oncology is 7.14. The forecasts range from a low of 5.05 to a high of $9.45. ….
Reader Q&A - also see RECOMMENDED ARTICLES & FAQs. Pyxis oncology stock prediction. Possible cause: Not clear pyxis oncology stock prediction.
Feb 13, 2023 · As of February 13, 2023, the average one-year price target for Pyxis Oncology is $11.22. The forecasts range from a low of $4.04 to a high of $16.80. The average price target represents an ... Pyxis Oncology has assembled a differentiated portfolio of clinical assets, including antibody-drug conjugates (ADCs) and monoclonal antibody (mAb) …As of September 30, 2023, the outstanding number of shares of common stock of Pyxis Oncology was 44,294,092. About Pyxis Oncology, Inc. Pyxis Oncology, Inc. is a clinical-stage company focused on ...
Nov 26, 2023 · Pyxis Oncology, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody, which is in Phase 1 clinical trial for the treatment of solid tumors, including non-small cell lung cancer (NSCLC) without driver ... As of June 30, 2023, the outstanding number of shares of common stock of Pyxis Oncology was 39,376,941. About Pyxis Oncology, Inc. Pyxis Oncology, Inc. is a clinical-stage company focused on ...
cheap dental plans in florida A. The latest price target for Pyxis Oncology ( NASDAQ: PYXS) was reported by RBC Capital on Tuesday, September 5, 2023. The analyst firm set a price target for 7.00 expecting PYXS to rise to ...May 24, 2023 · Under the terms of the definitive merger agreement, Pyxis Oncology expects to issue approximately 4.4 million shares of its common stock to Apexigen stockholders to acquire Apexigen. For each ... flng stock dividendchargpoint stock 0.73%. $39.94B. Astellas Pharma Inc. -4.37%. ¥3.42T. PYXS | Complete Pyxis Oncology Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. which brokers use metatrader 5 Comparatively, Pyxis Oncology has a beta of 1.13, suggesting that its stock price is 13% more volatile than the S&P 500. Summary Pyxis Oncology beats Aclaris Therapeutics on 10 of the 17 factors compared between the two stocks.Stock Price Prediction: Update at 5:00pm EST: If tomorrow: ... 2.68 - 2.7 2.7 - 2.72 Company Description: Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. ... BLKB, EDBL, SI… - Nasdaq Mon, 27 Mar 2023 Pyxis Oncology Stock: Cashed Up And Entering The Clinic ... forex trading on thinkorswimyeti holdings incplanet fitness bill 141.12%. Get the latest Pyxis Oncology Inc (PYXS) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and …About Pyxis Oncology, Inc. Pyxis Oncology, Inc. is a clinical-stage company focused on defeating difficult-to-treat cancers. The company is efficiently building next-generation therapeutics that hold the potential for mono and combination therapies. Pyxis Oncology’s therapeutic candidates are designed to directly kill tumor cells and to ... best japanese stocks Mar 22, 2023 · Full-Year 2022 Financial Results. As of December 31, 2022, Pyxis Oncology had cash and cash equivalents (including restricted cash) of $180.7 million, which is expected to fund operations into the ... penn stovkoil penny stocks under 10 centscrowdstrike share price As of May 10, 2023, the outstanding number of shares of common stock of Pyxis Oncology was 38,245,287. About Pyxis Oncology, Inc. Pyxis Oncology, Inc. is a clinical stage company focused on defeating difficult-to-treat cancers. The company is efficiently building next-generation therapeutics that hold the potential for mono and combination ...